Watertown, United States
Entact Bio is a biopharmaceutical and biotechnology startup founded in 2019 with a mission to develop a new class of precision medicines that enhance the function of beneficial proteins. The company's proprietary Encompass™ platform is designed to create enhancement-targeting chimeric (ENTAC™) medicines, leveraging the natural ability of deubiquitinases (DUBs) to regulate and enhance protein function.
Entact Bio's founding team, deeply rooted in DUB biochemistry, chemical biology, disease biology, and small-molecule drug development, has positioned the company to expand the universe of treatable diseases and provide new therapeutic options for patients who are underserved by current modalities.
The company, based in the United States, received a significant $39.90M venture round investment on 31 January 2024, indicating a strong vote of confidence from the investment community in its innovative approach to drug development. The investors behind this latest round of funding have not been disclosed.
